A Molecular Model For The Prediction Of Progression Free Survival In Young Mantle Cell Lymphoma Patients Treated With Cytarabine-Based High Dose Sequential Chemotherapy And Autologous Stem Cell Transplantation: Results From The Mcl0208 Phase Iii Trial From Fondazione Italiana Linfomi (Fil)

Background. Recent studies have described the landscape of recurrently mutated genes in mantle cell lymphoma (MCL), including genes involved in DNA damage response/cell cycle (ATM, TP53, CCND1), epigenetic regulation (KMT2D also known as MLL2, WHSC1), and cell signaling (BIRC3, TRAF2, NOTCH1). However, with the exception of TP53 abnormalities, little is known about the clinical relevance of recurrent mutations in MCL. Thus, we performed deep sequencing analysis of a MCL gene panel in the prospective series of patients enrolled in the ongoing FIL-MCL0208 phase III trial (EudraCTNumber: 2009-012807-25).